- Home
- MAIA vs IKNA Comparison
MAIA vs IKNA Comparison
Compare MAIA & IKNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MAIA
- IKNA
- Stock Information
- Founded
- MAIA 2018
- IKNA 2016
- Country
- MAIA United States
- IKNA United States
- Employees
- MAIA N/A
- IKNA N/A
- Industry
- MAIA Biotechnology: Pharmaceutical Preparations
- IKNA Biotechnology: Pharmaceutical Preparations
- Sector
- MAIA Health Care
- IKNA Health Care
- Exchange
- MAIA Nasdaq
- IKNA Nasdaq
- Market Cap
- MAIA 62.4M
- IKNA 83.0M
- IPO Year
- MAIA 2022
- IKNA 2021
- Fundamental
- Price
- MAIA $2.82
- IKNA $1.68
- Analyst Decision
- MAIA
- IKNA Buy
- Analyst Count
- MAIA 0
- IKNA 2
- Target Price
- MAIA N/A
- IKNA $3.00
- AVG Volume (30 Days)
- MAIA 60.0K
- IKNA 41.6K
- Earning Date
- MAIA 11-05-2024
- IKNA 11-07-2024
- Dividend Yield
- MAIA N/A
- IKNA N/A
- EPS Growth
- MAIA N/A
- IKNA N/A
- EPS
- MAIA N/A
- IKNA N/A
- Revenue
- MAIA N/A
- IKNA $1,844,000.00
- Revenue This Year
- MAIA N/A
- IKNA N/A
- Revenue Next Year
- MAIA N/A
- IKNA N/A
- P/E Ratio
- MAIA N/A
- IKNA N/A
- Revenue Growth
- MAIA N/A
- IKNA N/A
- 52 Week Low
- MAIA $0.82
- IKNA $1.02
- 52 Week High
- MAIA $5.99
- IKNA $4.63
- Technical
- Relative Strength Index (RSI)
- MAIA 50.98
- IKNA 51.57
- Support Level
- MAIA $2.36
- IKNA $1.68
- Resistance Level
- MAIA $2.72
- IKNA $1.78
- Average True Range (ATR)
- MAIA 0.22
- IKNA 0.04
- MACD
- MAIA 0.02
- IKNA 0.00
- Stochastic Oscillator
- MAIA 72.28
- IKNA 36.36
About MAIA MAIA Biotechnology Inc.
MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company. The company develops targeted immunotherapies for cancer. The company is an immune-oncology company, focused on the development of first-in-class drugs with novel mechanisms of action that are intended to meaningfully improve and extend the lives of people with cancer. The company's program is THIO, a potential cancer telomere-targeting agent in clinical development for the treatment of telomerase-positive cancer cells.
About IKNA Ikena Oncology Inc.
Ikena Oncology Inc is a targeted oncology company developing precision therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance in the Hippo and RAS onco-signaling network. Its targeted oncology product candidate, IK-930, is an oral small-molecule inhibitor of the transcriptional enhanced associate domain, or TEAD, a transcription factor in the Hippo signaling pathway, a known oncogenic pathway that also drives resistance to multiple targeted and chemotherapies. Its other product candidates are IK-175 and IK-595.